by A new category of weight loss medications is changing the landscape of obesity treatment for both ordinary people and medical experts. These medications, such as Ozempic and Wegovy, have been shown to effectively reduce feelings of hunger and promote weight loss of 15% or more. However, their impact on older adults remains uncertain, as clinical trials have not included significant numbers of individuals aged 65 and older.
The long-term effects of these new medications on older adults are still not well understood. Will they help prevent cardiovascular disease and other chronic illnesses in obese older adults? Will they improve mobility and daily functioning? Will they alleviate symptoms associated with obesity-related chronic conditions? These questions remain unanswered due to the lack of data.
One major barrier to access for seniors is the high cost of these medications. Medicare does not cover weight loss drugs, and the cost can exceed $10,000 per year. However, there is an exception for individuals with diabetes, as Medicare covers diabetes therapies like Ozempic and Mounjaro. This limited access to weight loss medications frustrates healthcare professionals who believe that these drugs could greatly benefit their patients.
A bipartisan group of lawmakers has proposed the Treat and Reduce Obesity Act, which would require Medicare to cover weight loss drugs. However, concerns about the potential costs for Medicare, estimated to exceed $13.5 billion if all beneficiaries with an obesity diagnosis took the drugs, have impeded progress on the legislation.
Experts unanimously agree that individuals with a body mass index (BMI) over 30, or a BMI of 27 or above with at least one obesity-related condition, should consider these medications. However, using BMI as a measure for older adults can be problematic, as it may not accurately assess body fat. Some experts suggest examining waist circumference instead, as abdominal fat poses a higher risk than fat carried in other areas of the body.
While weight loss can reduce the risk of mortality in adults with obesity, it is not recommended as the sole treatment for older adults. Weight loss in older adults often results in the loss of muscle mass, which can contribute to frailty and functional decline. The preservation of muscle mass is crucial, and older adults should be prescribed physical activity, including aerobic exercise and strength training.
Diet is also important, and older adults taking weight loss medications should ensure they are consuming adequate protein and calcium to preserve bone and muscle mass. Ongoing monitoring is necessary to address gastrointestinal side effects and ensure that seniors are receiving enough food and water. Additionally, a comprehensive approach that includes lifestyle changes and behavioral interventions is necessary for long-term success.
In conclusion, the emergence of new weight loss medications presents both opportunities and challenges for seniors. While these drugs hold promise in addressing obesity, their impact on older adults requires further research. Access to these medications remains limited due to high costs, although efforts are being made to expand coverage. A holistic approach that includes physical activity, a balanced diet, and behavioral changes is essential to ensuring long-term health among older adults dealing with obesity.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc.
